Epidemiology of generalized pustular psoriasis in Germany: Analyzing factors influencing prevalence estimates health insurance data
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025
DOI: 10.1111/ddg.15633 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2025. Verfasst von Michael Schultze und 4 weiteren Autor:innen. Beteiligte Einrichtung: ZEG - Berlin Center for Epidemiology and Health Research, Berlin, Germany. Hauptthemen laut MEDLINE: Psoriasis, Insurance, Health. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Background and Objectives : Generalized pustular psoriasis (GPP) is a rare, chronic, potentially life‐threatening skin disease. We aimed to establish criteria to accurately approximate GPP prevalence in Germany.
Methods
A retrospective analysis of the WIG2 health claims database (1/1/2016–31/12/2020) was conducted. Patients aged ≥ 12 years continuously enrolled in their statutory health insurance with one inpatient or confirmed outpatient diagnosis code for GPP (International Classification of Diseases, 10 th Revision [ICD‐10] L40.1) were included. Scenarios with increasingly strict criteria were used to identify the GPP population.
Results
From 2016–2020, 5,236 potential GPP cases were identified based on a recorded GPP diagnosis. The scenario of ≥ 1 GPP diagnosis yielded the highest prevalence (336–390 patients/million) followed by > 1 GPP diagnosis in ≥ 2 quarters (189–288 patients/million); scenarios resulting in the lowest prevalence were diagnosis in ≥ 2 quarters AND two independent diagnoses (17–28/million) and diagnosis in ≥ 2 quarters AND two independent diagnoses or diagnosis by a specialist AND potential flare (58–61 patients/million).
Conclusions
This study suggests that diagnosis in ≥ 2 quarters by a specialist or two independent physicians may be the most clinically robust and reliable criteria for estimating GPP prevalence; therefore, 50–100 patients/million may represent a reasonable prevalence estimate range for Germany.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ZEG - Berlin Center for Epidemiology and Health Research, Berlin, Germany.
- WIG2 - Scientific Institute for Health Economics and Health System Research, Leipzig, Germany.
- Department of Dermatology, Venereology, and Allergology, University Medical Center, Göttingen, Göttingen, Germany.
- Boehringer Ingelheim International GmbH, Ingelheim, Germany.
ORCID-Profile: Christian Kromer
Förderung
- Boehringer Ingelheim
Zitieren
APA
Schultze, M., Kossack, N., Kromer, C., Zimmermann, T. M., & Kolb, N. (2025). Epidemiology of generalized pustular psoriasis in Germany: Analyzing factors influencing prevalence estimates health insurance data. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15633
Vancouver
Schultze M, Kossack N, Kromer C, Zimmermann TM, Kolb N. Epidemiology of generalized pustular psoriasis in Germany: Analyzing factors influencing prevalence estimates health insurance data. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025. doi:10.1111/ddg.15633
BibTeX
@article{Schultze2025,
author = {Schultze, Michael and Kossack, Nils and Kromer, Christian and Zimmermann, Thomas M and Kolb, Nikolaus},
title = {Epidemiology of generalized pustular psoriasis in Germany: Analyzing factors influencing prevalence estimates health insurance data},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2025},
doi = {10.1111/ddg.15633}
}
EUVIMED